ANGOSTURA
12.2.2020 18:47:05 CET | Business Wire | Press release
The House of Angostura® has announced that world-renowned Trinidadian-born DJ, music producer and entrepreneur Christopher “Jillionaire” Leacock will add some star quality to the judging panel, and the celebration, at this year’s Angostura Global Cocktail Challenge. This biannual event, celebrates its 10th anniversary in 2020 and brings together bartenders worldwide for the chance to become the global champion. The Angostura® Global Cocktail Challenge Finals takes place on February 22 in Trinidad & Tobago, ahead of the greatest show on earth, Trinidad & Tobago Carnival.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200212005699/en/
Peter Sandström, CEO of Angostura® , comments: “The Angostura® Global Cocktail Challenge is the 10th anniversary of the competition and we wanted to do something special to mark the occasion. Partnering with Jillionaire made so much sense as his roots are inherently connected to the House of Angostura® . He has a strong understanding of Angostura’s place at the heart of Trinidad & Tobago culture, enormous passion for locally inspired music and drinks and his global following helps elevate the competition to showcase the extraordinary talents of our competitors to an international audience.”
The nine finalists of the Angostura® Global Cocktail Competition 2020 are: Shana Rajahram (Trinidad & Tobago), Marv Cunningham (The Bahamas), Chad Lawrence (Canada), Gustavo Costa (Brazil), Mike Jordhoy (France), Rohan Massie (Australia), Simon Dacey (United Kingdom), Vasile Dorofeev (Dubai) and Agung Satria (Vietnam).
Jillionaire, best known for his contributions to Major Lazer, an American electronic music group, brings a keen interest and understanding of the bar industry as part-owner of Clyde’s, a Trinidadian cocktail bar in Brooklyn, New York. He is well prepared to see the nine finalists compete, as they aim to wow the judges with cocktail prowess.
Jillionaire shares why he’s proud to join the Angostura® Global Cocktail Challenge judging panel: “I am a proud supporter of Trinidadian culture and have a personal interest in cocktail culture and one of our island’s biggest exporter - Angostura® . Angostura’s historic bitters are known the world over. I’m keen to shine a light on our celebrated rum and amaro which capture the flavours of Trinidad & Tobago. Whoever goes on to win the competition, will not only be representing Angostura® , they’ll be representing our island on the world stage, something I take seriously.”
Angostura Global Cocktail Competition Master of Ceremonies and Judging Panel
Jillionaire will join head judge and James Beard Award-winning beverage professional, Maxwell Britten. Other judges include Eryn Reece, Bar Director at The Wooly Public, Joe Schofield, co-owner of Schofield’s Bar, Angostura® Chief Brand Educator, Raymond Edwards, and the reigning Angostura® Global Cocktail Challenge Champion, Raymond Letoa. Hospitality industry veteran Ms Franky Marshall will serve as Master of Ceremonies. After the competition, Jillionaire will lead the after-party celebrations, performing a curated DJ set.
The winning bartender will receive the coveted title of “Angostura® Global Cocktail Challenge (AGCC) Champion,” a cash prize of US$10,000 and a two-year contract as the Angostura® Global Brand Ambassador for ANGOSTURA® aromatic bitters, ANGOSTURA® orange bitters, Angostura® Rums and Amaro di ANGOSTURA® , as well as the opportunity to revisit Angostura’s home in Trinidad & Tobago to serve as a judge at the next edition of the competition.
For more information about the competition, visit www.AngosturaGlobalCocktailChallenge.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200212005699/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom